Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation

European Neuropsychopharmacology

Volumn 25, Issue 9, 2015, Pages 1470-1479

  Maggio, Roberto ^a   Scarselli, Marco ^b   Capannolo, Marta ^a   Millan, Mark J ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Antiparkinson; Antipsychotic; Aripiprazole; G protein; Heteromerization; PHNO

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HOMODIMER; LEVODOPA; MONOMER; NAXAGOLIDE; NEUROLEPTIC AGENT; PARTIAL AGONIST; DOPAMINE RECEPTOR STIMULATING AGENT;

ALLOSTERISM; ARTICLE; BINDING KINETICS; BINDING SITE; CHO CELL LINE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; HETERODIMERIZATION; HUMAN; INTRINSIC ACTIVITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POLYMERIZATION; PRIORITY JOURNAL; TRANSACTIVATION; ANIMAL; DIMERIZATION; METABOLISM; TRANSCRIPTION INITIATION;

ALLOSTERIC REGULATION; ANIMALS; DIMERIZATION; DOPAMINE AGENTS; HUMANS; RECEPTORS, DOPAMINE D3; TRANSCRIPTIONAL ACTIVATION;

EID: 84941314193     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.09.016     Document Type: Article

References (53)

1. Aihara K., Shimada J., Miwa T., Tottori K., Burris K.D., Yocca F.D., Horie M., Kikuchi T. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004, 1003:9-17.
2. Armentero M.T., Pinna A., Ferré S., Lanciego J.L., Müller C.E., Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 2011, 132:280-299.
3. Azdad K., Gall D., Woods A.S., Ledent C., Ferré S., Schiffmann S.N. Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 2009, 34:972-986.
4. Banères J.L., Parello J. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J. Mol. Biol. 2003, 329:815-829.
5. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
6. Carrillo J.J., Pediani J., Milligan G. Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J. Biol. Chem. 2003, 278:42578-42587.
7. Castorina A., Leggio G.M., Giunta S., Magro G., Scapagnini G., Drago F., D'Agata V. Neurofibromin and amyloid precursor protein expression in dopamine D3 receptor knock-out mice brains. Neurochem. Res. 2011, 36:426-434.
8. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., Shi L., Newman A.H., Javitch J.A., Cherezov V., Stevens R.C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330:1091-1095.
9. Daniels D.J., Lenard N.R., Etienne C.L., Law P.Y., Roerig S.C., Portoghese P.S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. USA 2005, 102:19208-19213.
10. Diaz L., Pilon C., Le Foll B., Gross C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20:8677-8684.
11. Ferré S., LluiDs C., Lanciego J.L., Franco R. Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamineD(1)-D(3) receptor heteromer. CNS Neurol. Disord. Drug Targets 2010, 9:596-600.
12. Ferré S., Casadó V., Devi L.A., Filizola M., Jockers R., Lohse M.J., Milligan G., Pin J.P., Guitart X. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol. Rev. 2014, 66:413-434.
13. Fiorentini C., Busi C., Gorruso E., Gotti C., Spano P., Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 2008, 74:59-69.
14. Foley P., Gerlach M., Double K.L., Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. 2004, 111:1375-1446.
15. Fukuzaki K., Kamenosono T., Nagata R. Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol. Biochem. Behav. 2000, 65:503-508.
16. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
17. Han Y., Moreira I.S., Urizar E., Weinstein H., Javitch J.A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 2009, 5:688-695.
18. Jones K.A., Borowsky B., Tamm J.A., Craig D.A., Durkin M.M., Dai M., Yao W.J., Johnson M., Gunwaldsen C., Huang L.Y., Tang C., Shen Q., Salon J.A., Morse K., Laz T., Smith K.E., Nagarathnam D., Noble S.A., Branchek T.A., Gerald C. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 1998, 396:674-679.
19. Joyce J.N., Millan M.J. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr. Opin. Pharmacol. 2007, 7:100-105.
20. Koschatzky S., Gmeiner P. Selective agonists for dopamine/neurotensin receptor heterodimers. Chem. Med. Chem. 2012, 7:509-514.
21. Lee S.P., So C.H., Rashid A.J., Varghese G., Cheng R., Lanca A.J., O'Dowd B.F., George S.R. Dopamine D1 and D2 receptor coactivation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 2004, 279:35671-35678.
22. Maggio R., Vogel Z., Wess J. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc. Natl. Acad. Sci. USA 1993, 90:3103-3107.
23. Maggio R., Scarselli M., Novi F., Millan M.J., Corsini G.U. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J. Neurochem. 2003, 87:631-641.
24. Maggio R., Innamorati G., Parenti M. G protein-coupled receptor oligomerization provides the framework for signal discrimination. J. Neurochem. 2007, 103:1741-1752.
25. Maggio R., Aloisi G., Silvano E., Rossi M., Millan M.J. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism Relat. Disord. 2009, 15:S2-S7.
26. Marsango S., Caltabiano G., Pou C., Milligan G. The quaternary structure of dopamine D2 and D3 receptors: comparisons of the homo-oligomerisation of two closely related G protein-coupled receptors. Proc. Br. Pharmacol. Soc. 2014, 12(1):004. (Aastract).
27. Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease. Clin. Neuropharmacol. 1995, 18:S195-S206.
28. Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin J.-A., Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 2002, 303:791-804.
29. Millan M.J., Di Cara B., Hill M., Jackson M., Joyce J.N., Brotchie J., McGuire S., Crossman A., Smith L., Jenner P., Gobert A., Peglion J.L., Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J. Pharmacol. Exp. Ther. 2004, 309:921-935.
30. Millan M.J., Brocco M., Papp M., Serres F., La Rochelle C.D., Sharp T., Peglion J.L., Dekeyne A. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J. Pharmacol. Exp. Ther. 2004, 309:936-950.
31. Millan M.J., Brocco M. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) and D(2) antagonist, S33138. Therapie 2008, 63:187-229.
32. Millan M.J., Fone K., Steckler T., Horan W.P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur. Neuropsychopharmacol. 2014, 24:645-692.
33. Narendran R., Slifstein M., Guillin O., Hwang Y., Hwang D.R., Scher E., Reeder S., Rabiner E., Laruelle M. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006, 60:485-495.
34. Navarro G., Ferré S., Cordomi A., Moreno E., Mallol J., Casadó V., Cortés A., Hoffmann H., Ortiz J., Canela E.I., Lluís C., Pardo L., Franco R., Woods A.S. Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J. Biol. Chem. 2010, 285:27346-27359.
35. Nimchinsky E.A., Hof P.R., Janssen W.G., Morrison J.H., Schmauss C. Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J. Biol. Chem. 1997, 272:29229-29237.
36. Novi F., Millan M.J., Corsini G.U., Maggio R. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. J. Neurochem. 2007, 102:1410-1424.
37. O'Dowd B.F., Ji X., Nguyen T., George S.R. Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. Biochem. Biophys. Res. Commun. 2012, 417:23-28.
38. O'Dowd B.F., Nguyen T., Ji X., George S.R. D5 dopamine receptor carboxyl tail involved in D5-D2 heteromer formation. Biochem. Biophys. Res. Commun. 2013, 431:586-589.
39. Papaleo F., Yang F., Garcia S., Chen J., Lu B., Crawley J.N., Weinberger D.R. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 2012, 17:85-98.
40. Pei L., Li S., Wang M., Diwan M., Anisman H., Fletcher P.J., Nobrega J.N., Liu F. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat. Med. 2010, 16:1393-1395.
41. Perreault M.L., Jones-Tabah J., O'Dowd B.F., George S.R. A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. Int. J. Neuropsychopharmacol. 2013, 25:1-7.
42. Pou C., Mannoury la Cour C., Stoddart L.A., Millan M.J., Milligan G. Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface. J. Biol. Chem. 2012, 287:8864-8878.
43. Rasmussen S.G., DeVree B.T., Zou Y., Kruse A.C., Chung K.Y., Kobilka T.S., Thian F.S., Chae P.S., Pardon E., Calinski D., Mathiesen J.M., Shah S.T., Lyons J.A., Caffrey M., Gellman S.H., Steyaert J., Skiniotis G., Weis W.I., Sunahara R.K., Kobilka B.K. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
44. Robinson S.W., Caron M.G. Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells. J Neurochem 1996, 67:212-219.
45. Scarselli M., Armogida M., Chiacchio S., DeMontis M.G., Colzi A., Corsini G.U., Maggio R. Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments. Eur. J. Pharmacol. 2000, 397:291-296.
46. Scarselli M., Novi F., Schallmach E., Lin R., Baragli A., Colzi A., Griffon N., Corsini G.U., Sokoloff P., Levenson R., Vogel Z., Maggio R. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 2001, 276:30308-30314.
47. Scarselli M., Novi F., Corsini G.U., Maggio R. Functional rescue of the inactive splice variant of the dopamine D3 receptor D3nf. Brain Res. 2003, 987:244-247.
48. Seeman P., Wilson A., Gmeiner P., Kapur S. Dopamine D2 and D3 receptors in human putamen, caudate nucleus and globus pallidus. Synapse 2006, 60:205-211.
49. 2 receptor. G-protein-coupled-receptors: from structural insights to functional mechanisms. 2012, 12-14. Monash University, Prato Centre, Italy, (September 2012, P006).
50. Silvano E., Millan M.J., Mannoury la Cour C., Han Y., Duan L., Griffin S.A., Luedtke R.R., Aloisi G., Rossi M., Zazzeroni F., Javitch J.A., Maggio R. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Mol. Pharmacol. 2010, 78:925-934.
51. Tamminga C.A., Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr. Drug. Targets CNS Neurol. Disord. 2002, 1:141-147.
52. Torvinen M., Marcellino D., Canals M., Agnati L.F., Lluis C., Franco R., Fuxe K. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol. Pharmacol. 2005, 67:400-407.
53. Whorton M.R., Bokoch M.P., Rasmussen S.G., Huang B., Zare R.N., Kobilka B., Sunahara R.K. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. USA 2007, 104:7682-7687.